VJHemOnc Podcast iwMDS 2022: Key highlights
Sep 29, 2022
Experts discuss key highlights from the 1st International Workshop on Myelodysplastic Syndromes, including immune dysregulation in MDS, improving drug approvals, treating high-risk disease, and challenges in the field. They also explore the significance of patient-related factors in clinical trial design, advancements in high-risk MDS trials, novel agents for lower risk MDS, and the challenges of drug access in different countries.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Improving Clinical Trial Design for MDS Patients: Focus on Quality of Life and Frailty
02:56 • 3min
Advancements in High-Risk MDS Clinical Trials
05:31 • 3min
Novel Agents and Ongoing Clinical Trials in Lower Risk MDS
08:33 • 3min
Drug Access and Frustrations in Different Countries
11:05 • 4min